Your browser is no longer supported. Please, upgrade your browser.
Settings
NK NantKwest daily Stock Chart
NK [NASD]
NantKwest
Index- P/E- EPS (ttm)-1.47 Insider Own1.10% Shs Outstand80.83M Perf Week-5.87%
Market Cap259.46M Forward P/E- EPS next Y-1.59 Insider Trans-2.86% Shs Float29.78M Perf Month-6.41%
Income-120.80M PEG- EPS next Q-0.35 Inst Own19.80% Short Float12.13% Perf Quarter-49.69%
Sales0.04M P/S5896.92 EPS this Y55.50% Inst Trans-0.01% Short Ratio10.96 Perf Half Y-51.87%
Book/sh3.58 P/B0.90 EPS next Y-6.00% ROA-35.80% Target Price6.80 Perf Year-67.18%
Cash/sh2.46 P/C1.30 EPS next 5Y-1.70% ROE-37.90% 52W Range2.83 - 10.09 Perf YTD-43.88%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-68.19% Beta-
Dividend %- Quick Ratio16.30 Sales past 5Y- Gross Margin- 52W Low13.43% ATR0.22
Employees82 Current Ratio16.30 Sales Q/Q0.00% Oper. Margin- RSI (14)38.27 Volatility4.74% 6.53%
OptionableYes Debt/Eq0.01 EPS Q/Q68.70% Profit Margin- Rel Volume0.62 Prev Close3.31
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume329.55K Price3.21
Recom2.20 SMA20-4.46% SMA50-19.86% SMA200-47.86% Volume205,182 Change-3.02%
Mar-17-17Reiterated FBR & Co. Outperform $22 → $9
Jan-24-17Downgrade Jefferies Buy → Hold
Jun-02-16Initiated Raymond James Mkt Perform
Apr-04-16Reiterated Canaccord Genuity Buy $20 → $18
Mar-31-16Reiterated FBR Capital Outperform $30 → $29
Dec-22-15Initiated Canaccord Genuity Buy $20
Oct-28-15Initiated FBR Capital Outperform $30
Aug-24-15Initiated Piper Jaffray Overweight $38
Aug-24-15Initiated MLV & Co Buy $35
Aug-24-15Initiated Jefferies Buy $33
Aug-24-15Initiated Citigroup Buy $45
Apr-24-17 02:37PM  ETFs with exposure to NantKwest, Inc. : April 24, 2017 Capital Cube
Apr-07-17 05:08PM  ETFs with exposure to NantKwest, Inc. : April 7, 2017 Capital Cube
Apr-04-17 03:03PM  [$$] Funding Snapshot: Viracta Gets $18.4 Million from NantKwest for Cancer Drugs The Wall Street Journal
03:03PM  [$$] Funding Snapshot: Viracta Gets $18.4 Million from NantKwest for Cancer Drugs
08:00AM  NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership GlobeNewswire
08:00AM  NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
Mar-27-17 04:01PM  ETFs with exposure to NantKwest, Inc. : March 27, 2017 Capital Cube +6.19%
04:01PM  ETFs with exposure to NantKwest, Inc. : March 27, 2017
Mar-21-17 01:04PM  NANTKWEST, INC. Financials -6.76%
11:38AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube
11:38AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
09:59AM  NantKwest, Inc. :NK-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
Mar-20-17 07:00AM  NantKwest Announces FDA Grant of Orphan Drug Designation for the Companys aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma Business Wire
Mar-15-17 04:22PM  NANTKWEST, INC. Files SEC form 10-K, Annual Report +7.02%
Mar-06-17 05:00AM  NantKwest to Present at Upcoming Investor Conferences Business Wire -5.15%
Jan-24-17 09:26AM  Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo -11.44%
06:44AM  NantKwest downgraded by Jefferies
Jan-23-17 12:47PM  Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer Business Wire
Jan-11-17 11:18AM  NantKwest, Inc. Value Analysis (NASDAQ:NK) : January 11, 2017 Capital Cube
11:18AM  NantKwest, Inc. Value Analysis (NASDAQ:NK) : January 11, 2017
Jan-10-17 07:19AM  NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : January 10, 2017 Capital Cube
07:19AM  NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : January 10, 2017
Dec-19-16 05:00AM  NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs Business Wire
Dec-16-16 02:05PM  ETFs with exposure to NantKwest, Inc. : December 16, 2016
12:13AM  How Nantkwest Inc (NK) Stacks Up Versus Peers at Insider Monkey
Dec-12-16 11:44AM  NantKwest Announces Enhanced High-Affinity Activated Natural Killer (haNK) Cell Therapy in Preclinical Studies of HER2 Positive Breast Cancer at Presentation at the San Antonio Breast Cancer Symposium Business Wire
Dec-08-16 08:43AM  Why NantKwest (NK) Stock Might be a Great Pick
Nov-29-16 07:27AM  NantKwest, Inc. breached its 50 day moving average in a Bearish Manner : NK-US : November 29, 2016
Nov-28-16 01:13PM  NantKwest to Present at the Piper Jaffray 28th Annual Health Care Conference Business Wire -5.49%
Nov-23-16 01:17PM  ETFs with exposure to NantKwest, Inc. : November 23, 2016
Nov-22-16 08:17PM  Direct Injection of CAR-Engineered CD19.taNK Cells Demonstrating Potential Vaccine Protective Effect to be Highlighted in Oral Presentation at the 58th Annual Meeting of the American Society of Hematology Business Wire
11:43AM  NantKwest Announces Landmark Study Published on high affinity haNK Cell Therapy in the Journal Oncotarget Business Wire
Nov-21-16 10:38AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016
Nov-14-16 04:08PM  NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors Business Wire
Nov-11-16 07:02AM  NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : November 11, 2016
Nov-10-16 04:05PM  NANTKWEST, INC. Files SEC form 10-Q, Quarterly Report
Nov-08-16 08:21PM  NantKwest to Present Data at the 58th Annual Meeting of the American Society of Hematology Business Wire
Oct-24-16 12:27PM  ETFs with exposure to NantKwest, Inc. : October 24, 2016
Oct-19-16 07:05AM  Better Buy: NantKwest, Inc. vs. Celldex Therapeutics, Inc. at Motley Fool
Oct-04-16 10:00AM  Altor BioScience Corporation and NantKwest Inc. Announce Co-Development Agreement to Advance Innovative Natural Killer Cell Combination Immunotherapies for the Treatment of Cancer Business Wire
Oct-03-16 12:24PM  NantKwest, Inc. Value Analysis (NASDAQ:NK) : October 3, 2016
07:00AM  NantKwest Announces Presentations at the Upcoming 16th Annual Meeting of the Society for Natural Immunity Business Wire
Sep-30-16 08:25AM  NantKwest, Inc. breached its 50 day moving average in a Bearish Manner : NK-US : September 30, 2016 +5.14%
Sep-21-16 10:51AM  ETFs with exposure to NantKwest, Inc. : September 21, 2016
Sep-10-16 10:36PM  NantKwest Announces Presentations at Upcoming Investment Conferences Business Wire
05:55PM  Are These 3 Clinical-Stage Biotechs Still Buys After Soaring in August? at Motley Fool
Aug-31-16 11:39AM  ETFs with exposure to NantKwest, Inc. : August 31, 2016
Aug-29-16 06:09AM  NANTKWEST, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Aug-19-16 01:04PM  ETFs with exposure to NantKwest, Inc. : August 19, 2016
Aug-18-16 11:05AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016
Aug-16-16 06:20AM  NantKwest reports 2Q loss
Aug-15-16 12:04PM  NANTKWEST, INC. Files SEC form 10-Q, Quarterly Report
Jul-28-16 10:08AM  These 5 Stocks Under $10 Are Set to Soar Higher
Jul-23-16 02:01PM  Breakthrough Cancer Treatment Stocks Every Investor Ought to Know About at Motley Fool
Jul-19-16 02:44PM  NantKwest, Inc. Value Analysis (NASDAQ:NK) : July 19, 2016 -7.09%
12:52PM  ETFs with exposure to NantKwest, Inc. : July 19, 2016
Jul-13-16 08:45AM  NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : July 13, 2016 -8.97%
Jun-30-16 12:23PM  ETFs with exposure to NantKwest, Inc. : June 30, 2016
Jun-28-16 09:21AM  Better Buy: NantKwest, Inc. vs. Ionis Pharmaceuticals at Motley Fool
Jun-20-16 09:02AM  NANTKWEST, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-08-16 02:25PM  ETFs with exposure to NantKwest, Inc. : June 8, 2016
Jun-07-16 11:07AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016
Jun-04-16 07:39PM  After NantHealth IPO, Patrick Soon-Shiong Prepares for Two More
Jun-02-16 03:32PM  Soon-Shiong's Latest Offering Is Risky at Bloomberg
May-20-16 04:47PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NantKwest, Inc. of Class Action Lawsuit and Upcoming Deadline NK GlobeNewswire
11:49AM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of NantKwest, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 23, 2016 - NK PR Newswire
May-19-16 04:03PM  EXPANDED CLASS PERIOD: Goldberg Law PC Files Securities Class Action Lawsuit Against NantKwest, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire -14.52%
01:28PM  The Law Offices of Howard G. Smith Announces an Expanded Class Period in the Securities Class Action Lawsuit Pending Against NantKwest, Inc. Business Wire
12:03PM  DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit Against NantKwest, Inc. And Reminds Investors With Losses To Contact The Firm Accesswire
10:02AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nantkwest, Inc. (NK) and Lead Plaintiff Deadline: May 23, 2016 Accesswire
May-18-16 05:47PM  Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against NantKwest, Inc. Business Wire
12:34PM  INVESTOR ALERT: Rosen Law Firm Reminds NantKwest, Inc. Investors of Important May 23 Deadline In Class Action - NK GlobeNewswire
May-17-16 11:10AM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against NantKwest, Inc. And Encourages Investors With Losses To Contact The Firm Accesswire
08:00AM  NantKwest Provides Update on Clinical Programs at Bank of America Healthcare Conference Multiple Immunotherapy Combinations Announced as Part of Cancer Moonshot 2020 Initiative Business Wire
May-16-16 02:49PM  INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Action Lawsuit Involving NantKwest, Inc. and a Lead Plaintiff Deadline of May 23, 2016 - NK GlobeNewswire
12:04PM  NANTKWEST, INC. Files SEC form 10-Q, Quarterly Report
May-13-16 01:45PM  Hagens Berman Advises NantKwest, Inc. (NASDAQ: NK) Investors of Investigation to Expand Class Period to Include IPO and May 23rd Lead Plaintiff Deadline GlobeNewswire
May-12-16 11:17AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of NantKwest, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 23, 2016 NK GlobeNewswire -12.65%
May-11-16 10:02AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Nantkwest, Inc. (NK) and Lead Plaintiff Deadline: May 23, 2016 Accesswire -5.02%
May-06-16 12:24PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of NantKwest, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 23, 2016 Business Wire +5.96%
May-05-16 01:14PM  Lifshitz & Miller Law Firm Announces Investigation of Alere Inc., First NBC Bank Holding Company, NantKwest, Inc., Platform Specialty Products Corporation, Santander Consumer USA Holdings Inc., and Sempra Energy PR Newswire
May-04-16 11:22AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against NantKwest, Inc. (NK) and Lead Plaintiff Deadline: May 23, 2016 PR Newswire
May-03-16 02:23PM  ETFs with exposure to NantKwest, Inc. : May 3, 2016 at Capital Cube
May-02-16 05:10PM  SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Lawsuit Involving NantKwest, Inc. and a Lead Plaintiff Deadline of May 23, 2016 Business Wire
09:03AM  NantKwest, Inc. breached its 50 day moving average in a Bearish Manner : NK-US : May 2, 2016 at Capital Cube
Apr-29-16 07:03PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NantKwest, Inc. of Class Action Lawsuit and Upcoming Deadline - NK Accesswire
Apr-28-16 01:57PM  Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of NantKwest, Inc. Investors and Encourages Investors to Contact the Firm Business Wire
08:25AM  Patrick Soon-Shiong: Highest Paid CEO of 2015 (NK) at Investopedia
05:00AM  With $330 Million Award, Doctor Tops Banker in 2015 CEO Pay at Bloomberg
Apr-27-16 09:15PM  Cancer research firm NantKwest paid its billionaire chief $148 million last year at Los Angeles Times -8.01%
02:06PM  This CEO's $148 Million in Pay May Rank Him No. 1 for 2015 at Bloomberg
Apr-26-16 04:45PM  Investor Alert: The Law Offices of Vincent Wong Notifies Investors of Class Action Lawsuit Involving NantKwest, Inc. and a Lead Plaintiff Deadline of May 23, 2016 - NK PR Newswire
Apr-25-16 10:20AM  Lawsuit for Investors in NantKwest Inc (NASDAQ:NK) shares announced by Shareholders Foundation GlobeNewswire
Apr-22-16 05:10PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NantKwest, Inc. of Class Action Lawsuit and Upcoming Deadline - NK Accesswire
04:01PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against NantKwest, Inc. - NK GlobeNewswire
10:38AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of NantKwest, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 23, 2016 Business Wire
08:30AM  Hagens Berman Investigates Expanding NantKwest, Inc. (NASDAQ: NK) Class Period to Include IPO and Reminds Investors of May 23rd Lead Plaintiff Deadline GlobeNewswire
Apr-20-16 01:24PM  SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Lawsuit Involving NantKwest, Inc. and a Lead Plaintiff Deadline of May 23, 2016 Business Wire
10:30AM  The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NantKwest, Inc. Investors and Encourages Investors to Contact the Firm Business Wire
Apr-18-16 09:15PM  Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of NantKwest, Inc. Investors and Encourages Investors to Contact the Firm Business Wire
NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tajak Richard J.Chief Financial OfficerMar 23Option Exercise0.005,000014,859Mar 27 01:12 PM
Tajak Richard J.Chief Financial OfficerDec 23Option Exercise0.005,000011,575Dec 28 07:04 PM
Thomas John CDirectorNov 25Sale7.506,16846,260309,621Nov 29 05:42 PM
Thomas John CDirectorNov 23Sale7.507,00052,500315,789Nov 23 04:26 PM
Thomas John CDirectorNov 22Sale7.5013,00097,500322,789Nov 23 04:26 PM